Abstract
Twelve DSM-IIIR diagnosed schizophrenics, with neuroleptic-induced akathisia (NIA), were treated with either propranolol or matched placebo for two days, followed by a treatment crossover phase for five more days. Raters and patients were "blind" to treatment. This study shows that 120 mg of propranolol a day is more effective than placebo in reducing akathisia, and that propranolol's antiakathisic effect may require several days of treatment.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Akathisia, Drug-Induced
-
Antipsychotic Agents / administration & dosage
-
Antipsychotic Agents / adverse effects*
-
Benztropine / administration & dosage
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Humans
-
Neurologic Examination
-
Propranolol / administration & dosage*
-
Psychomotor Agitation / drug therapy*
-
Schizophrenia / drug therapy*
-
Schizophrenic Psychology*
Substances
-
Antipsychotic Agents
-
Benztropine
-
Propranolol